The overarching aim of establishing this cohort is to improve the outcomes of patients with PsA by understanding the factors that impact on them. Our approach will be two-fold. Firstly, we will longitudinally assess the natural history, treatment responses and impact of disease using validated instruments that assess disease activity and patient-reported outcomes such as disability, work-productivity and quality of life. Secondly, we will screen patients for metabolic co-morbidities such as hypertension, dyslipidaemia, obesity and non-alcoholic fatty liver disease (NAFLD). These data will allow us to understand the impact of PsA and its co-morbidities on our patients, identify modifiable prognostic factors that contribute to morbidity and mortality, and assess the yield of annual screening for metabolic syndrome. The clinical dataset will be available for collaboration with academia, patient groups, and industry, and will form the foundation for matching biomarker sample collection in the near future.
|Effective start/end date||1/01/20 → 31/12/20|
- Arthritis Australia: AUD50,000.00